Gulley, James L.

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 590

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 585

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 406

Current Landscape of Immunotherapy in Breast Cancer: A Review

Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 384

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Lind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 247

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Boyiadzis, M. M., Kirkwood, J. M., Marshall, J. L., Pritchard, C. C., Azad, N. S., & Gulley, J. L. (2018) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 219

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

David, J. M., Dominguez, C., McCampbell, K. K., Gulley, J. L., Schlom, J., & Palena, C. (2017) · OncoImmunology

TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers

Cited by 180

A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics

Hoang, D.-T., Dinstag, G., Shulman, E. D., Hermida, L. C., Ben-Zvi, D. S., Elis, E., Caley, K., Sammut, S.-J., Sinha, S., Sinha, N., et al. (2024) · Nature Cancer

AI in cancer detectionRadiomics and Machine Learning in Medical Imaging

Cited by 157

Applications of large language models in cancer care: current evidence and future perspectives

Iannantuono, G. M., Bracken-Clarke, D., Floudas, C. S., Roselli, M., Gulley, J. L., & Karzai, F. (2023) · Frontiers in Oncology

Artificial Intelligence in Healthcare and EducationAI in cancer detection

Cited by 115

Phase i trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma

Bilusic, M., Heery, C. R., Arlen, P. M., Rauckhorst, M., Apelian, D., Tsang, K. Y., Tucker, J. A., Jochems, C., Schlom, J., Gulley, J. L., et al. (2014) · Cancer Immunology, Immunotherapy

Immunotherapy and Immune ResponsesBacterial Cancer Therapy

Cited by 102

Product review: Avelumab, an anti-PD-L1 antibody

Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 91

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 62

Phase I study of oral lenalidomide in patients with refractory metastatic cancer

Dahut, W. L., Aragon‐Ching, J. B., Woo, S., Tohnya, T. M., Gulley, J. L., Arlen, P. M., Wright, J. J., Ventiz, J., & Figg, W. D. (2009) · The Journal of Clinical Pharmacology

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 56

A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population.

Karzai, F., Madan, R. A., Owens, H., Couvillon, A., Hankin, A., Williams, M., Bilusic, M., Cordes, L. M., Trepel, J. B., Killian, K., et al. (2018) · Journal of Clinical Oncology

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 50

A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver

Gulley, J. L., Madan, R. A., Tsang, K.-Y., Arlen, P. M., Camphausen, K., Mohebtash, M., Kamrava, M., Schlom, J., & Citrin, D. (2011) · Expert Opinion on Biological Therapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 26

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis

Robbins, Y., Friedman, J., Clavijo, P. E., Sievers, C., Bai, K., Donahue, R. N., Schlom, J., Sinkoe, A., Abdul Sater, H., Gulley, J. L., et al. (2021) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersHead and Neck Cancer Studies

Cited by 17